On March 8, 2022 Ambrx Biopharma Inc., or Ambrx (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, reported that Feng Tian, Ph.D., Chairman of the Board, President, and CEO of Ambrx, will present at Oppenheimer’s 32nd Annual Healthcare Conference taking place March 15-17, 2022 (Press release, Ambrx, MAR 8, 2022, View Source [SID1234609699]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Tian is scheduled to present on Thursday, March 17, at 12:40 p.m. Eastern Time.

Interested parties can access the live webcast for this conference from the Investor Relations section of the company’s website at www.ambrx.com. The webcast replay will be available after the conclusion of the panel discussion for approximately 90 days.